|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Dynasplint Systems, Inc. |
|---|---|
| Information provided by: | Dynasplint Systems, Inc. |
| ClinicalTrials.gov Identifier: | NCT00717691 |
Purpose
The purpose of this study is to regain range of motion of the great toe with dynamic splinting which will help reduce great toe's pain and swelling.
| Condition | Intervention |
|---|---|
|
Hallux Limitus |
Device: Metatarsophalangeal Extension Dynasplint System Other: Standard of Care |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Hallux Limitus Treated With Dynamic Splinting: A Randomized, Controlled Trial |
| Estimated Enrollment: | 50 |
| Study Start Date: | July 2008 |
| Study Completion Date: | December 2008 |
| Primary Completion Date: | October 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Immediate fitting with dynamic splinting following diagnosis of hallux limitus.
|
Device: Metatarsophalangeal Extension Dynasplint System
Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn for 30 minutes, three times per day, (while seated or resting in bed) totaling 1.5 hours per day.
Other: Standard of Care
The current standard of care in treating Hallux Limitus will be given to all patients regardless of randomized categorization, and this includes: analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs), orthotics with medial stiffness, and reduction of great toe movement in motions such as kneeling or squatting with the toes in an extended position.
|
|
No Intervention: 2
Control arm; patients only treated with standard of care following diagnosis of hallux limitus.
|
Other: Standard of Care
The current standard of care in treating Hallux Limitus will be given to all patients regardless of randomized categorization, and this includes: analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs), orthotics with medial stiffness, and reduction of great toe movement in motions such as kneeling or squatting with the toes in an extended position.
|
Determine the efficacy of dynamic splinting in treating patients with hallux limitus, in a randomized, controlled trial.
Eligibility| Ages Eligible for Study: | 18 Years to 90 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Georgia | |
| Atlanta Foot and Leg Clinic | |
| Jonesboro, Georgia, United States, 30236 | |
| Ankle and Foot Centers, PC | |
| Marietta, Georgia, United States, 30066 | |
| Principal Investigator: | Stanley R Kalish, DPM, FACFAS | Atlanta Foot and Leg Clinic |
| Study Director: | Buck Willis, PhD | Dynasplint Systems, Inc. |
More Information
| Responsible Party: | Buck Willis, PhD: Clinical Research Director, Dynasplint Systems, Inc. |
| ClinicalTrials.gov Identifier: | NCT00717691 History of Changes |
| Other Study ID Numbers: | 2008.003 |
| Study First Received: | July 15, 2008 |
| Last Updated: | June 5, 2009 |
| Health Authority: | United States: Institutional Review Board |
|
Hallux Limitus Dynamic Splinting Dynasplint |
|
Hallux Limitus Hallux Rigidus Foot Deformities, Acquired |
Foot Deformities Musculoskeletal Diseases Joint Diseases |